A

Akero Therapeutics
D

AKRO

44.910
USD
-0.37
(-0.82%)
مغلق
حجم التداول
62,053
الربح لكل سهم
-4
العائد الربحي
-
P/E
-12
حجم السوق
3,578,393,860
أصول ذات صلة
KAVAUSD
KAVAUSD
0.03923
(9.37%)
0.45787 USD
UMAUSD
UMAUSD
0.00024
(0.02%)
1.11583 USD
B
BAND
0.030
(0.24%)
12.470 USD
L
LINK
0.24000
(3.75%)
6.64000 USD
S
SOL
0.02500
(1.89%)
1.35000 USD
المزيد
الأخبار المقالات

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.